Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed ...

Summary: A Phase 2 randomized clinical trial demonstrates that a single 25 mg dose of psilocybin, combined with psychotherapeutic support, provides rapid, statistically significant, and clinically ...

Investigators found no evidence that management consulting firms improved finances, operations, or quality of care at nonprofit hospitals.

(Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin ...

The latest Fraud and Error in the Benefit System report estimates that 3.2 per cent of benefit expenditure was overpaid in ...

The latest Fraud and Error in the Benefit System report estimates 3.2 per cent of benefit spending was overpaid in the ...

Fri, May 15, 2026 The Department for Work and Pensions (DWP) has released new figures revealing that billions of pounds were ...

Progress has also slowed in reducing the risk of death from noninfectious diseases like cancer, diabetes and cardiovascular ...

New fraud and error figures show changes in claimants’ health and daily living needs accounted for most incorrect PIP ...

Regenxbio announces positive results from pivotal phase III AFFINITY DUCHENNE study of RGX-202 to treat Duchenne muscular dystrophy: Rockville, Maryland Friday, May 15, 2026, 14:0 ...

New Department for Work and Pensions figures show £9.9bn was overpaid across the benefit system last year, while £1.2bn was ...